

# Robert F Hobbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3031429/publications.pdf>

Version: 2024-02-01

107  
papers

5,519  
citations

117625

34  
h-index

82547

72  
g-index

109  
all docs

109  
docs citations

109  
times ranked

4130  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Improved <sup>211</sup> At-Labeled Agent for PSMA-Targeted $\beta$ -Therapy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 259-267.	5.0	28
2	Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered $\beta$ -Particles May Realize the Promise for <sup>225</sup> Ac in Large, Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1223-1230.	5.0	5
3	<sup>212</sup> Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro. <i>International Journal of Radiation Biology</i> , 2022, 98, 1452-1461.	1.8	4
4	I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response. <i>Annals of Nuclear Medicine</i> , 2022, 36, 213-223.	2.2	4
5	Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263717.	5.0	0
6	Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4382-4393.	6.4	4
7	Preclinical evaluation of <sup>213</sup> Bi- <sup>225</sup> Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256388.	5.0	17
8	Current Status of Radiopharmaceutical Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 891-901.	0.8	44
9	Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 905-912.	0.8	13
10	Superior Postimplant Dosimetry Achieved Using Dynamic Intraoperative Dosimetry for Permanent Prostate Brachytherapy. <i>Practical Radiation Oncology</i> , 2021, 11, 264-271.	2.1	1
11	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [ <sup>111</sup> In]In-XYIMSR <sup>01</sup> for phase I regulatory approval. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 243-250.	1.0	2
12	Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin <sup>®</sup> ) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. <i>Cancers</i> , 2021, 13, 2828.	3.7	8
13	Transport-driven engineering of liposomes for delivery of $\beta$ -particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4246-4258.	6.4	11
14	Abstract 1395: Humanized GD2 antibody for targeted radiopharmaceutical therapy of human and canine osteosarcoma. , 2021, , .		0
15	Renal <sup>99m</sup> Tc-DMSA pharmacokinetics in pediatric patients. <i>EJNMMI Physics</i> , 2021, 8, 53.	2.7	3
16	Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis. <i>EJNMMI Physics</i> , 2021, 8, 60.	2.7	11
17	Real-time quantitation of thyroidal radioiodine uptake in thyroid disease with monitoring by a collar detection device. <i>Scientific Reports</i> , 2021, 11, 18479.	3.3	2
18	DeepAMO: a multi-slice, multi-view anthropomorphic model observer for visual detection tasks performed on volume images. <i>Journal of Medical Imaging</i> , 2021, 8, 041204.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. <i>Theranostics</i> , 2021, 11, 9721-9737.	10.0	12
20	Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 18-29.	6.4	15
21	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 12S-22S.	5.0	14
22	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.	5.0	32
23	Human Radiation Dosimetry for Orally and Intravenously Administered <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2020, 61, 613-619.	5.0	11
24	Preclinical Evaluation of <sup>203</sup> Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 80-88.	5.0	59
25	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. <i>Cancer Research</i> , 2020, 80, 868-876.	0.9	10
26	Response of breast cancer carcinoma spheroids to combination therapy with radiation and DNA-PK inhibitor: growth arrest without a change in $\frac{D_{01}}{D_{02}}$ ratio. <i>International Journal of Radiation Biology</i> , 2020, 96, 1534-1540.	1.8	5
27	Radiopharmaceutical therapy in cancer: clinical advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 589-608.	46.4	370
28	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENs). <i>BMC Cancer</i> , 2020, 20, 492.	2.6	16
29	Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. <i>Theranostics</i> , 2020, 10, 2888-2896.	10.0	28
30	Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 124-132.	4.6	29
31	SAT-417 Personalized Treatment Planning for Radioiodine Therapy of Graves' Disease; The Collar Therapy Indicator (CoTI). <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
32	Dosimetric considerations of <sup>99m</sup> Tc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients. <i>Physics in Medicine and Biology</i> , 2020, 65, 235025.	3.0	3
33	Accuracy in dosimetry of diagnostic agents: impact of the number of source tissues used in whole organ S value-based calculations. <i>EJNMMI Research</i> , 2020, 10, 26.	2.5	2
34	Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc-99m DMSA and Tc-99m MAG3. <i>Physics in Medicine and Biology</i> , 2020, 65, 235026.	3.0	5
35	<sup>177</sup> Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2545-2557.	6.4	40
36	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	3.8	71

#	ARTICLE	IF	CITATIONS
37	Current pediatric administered activity guidelines for <sup>99m</sup> Tc <sup>99m</sup> DMSA SPECT based on patient weight do not provide the same task-based image quality. <i>Medical Physics</i> , 2019, 46, 4847-4856.	3.0	7
38	Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S33.	0.3	3
39	<sup>177</sup> Lu-Particle <sup>177</sup> Emitter Radiopharmaceutical Therapy: Resistance Is Futile. <i>Cancer Research</i> , 2019, 79, 5479-5481.	0.9	13
40	The Case for Dosimetry in Alpha-Emitter Therapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S45-S46.	0.3	3
41	<sup>68</sup> Ga-DOTATATE PET. <i>Nuclear Medicine Communications</i> , 2019, 40, 920-926.	1.1	8
42	Radiopharmaceutical Therapy. <i>Health Physics</i> , 2019, 116, 175-178.	0.5	19
43	Evaluation of <sup>111</sup> In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. <i>Journal of Nuclear Medicine</i> , 2019, 60, 400-406.	5.0	19
44	Combined model-based and patient-specific dosimetry for <sup>18</sup> F-DCFPyL, a PSMA-targeted PET agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 989-998.	6.4	12
45	Comparative Dosimetry for <sup>68</sup> Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1281-1288.	5.0	12
46	Targeted and Nontargeted <sup>177</sup> Lu-Particle Therapies. <i>Annual Review of Biomedical Engineering</i> , 2018, 20, 73-93.	12.3	46
47	Biodistribution and Radiation Dosimetry of <sup>124</sup> I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1751-1756.	5.0	22
48	Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy. <i>Brachytherapy</i> , 2018, 17, 858-865.	0.5	3
49	Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides. <i>Current Radiopharmaceuticals</i> , 2018, 11, 209-214.	0.8	20
50	Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in <sup>124</sup> I PET/CT-Based Dosimetry for <sup>131</sup> I Therapy of Metastatic Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1146-1154.	5.0	42
51	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1560-1566.	5.0	73
52	Dose Estimation in Pediatric Nuclear Medicine. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 118-125.	4.6	27
53	Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model. <i>Medical Physics</i> , 2017, 44, 272-283.	3.0	8
54	Depth-dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry. <i>Medical Physics</i> , 2017, 44, 747-761.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. <i>EJNMMI Research</i> , 2017, 7, 57.	2.5	35
56	Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 68071-68082.	1.8	6
57	Comparison of quantitative $^{90}\text{Y}$ SPECT and non- $^{\infty}$ PET imaging in post-therapy radioembolization of liver cancer. <i>Medical Physics</i> , 2016, 43, 5779-5790.	3.0	32
58	Absorbed-dose calculation for treatment of liver neoplasms with $^{90}\text{Y}$ -microspheres. <i>Clinical and Translational Imaging</i> , 2016, 4, 273-282.	2.1	6
59	A risk index for pediatric patients undergoing diagnostic imaging with $^{99\text{mTc}}$ -dimercaptosuccinic acid that accounts for body habitus. <i>Physics in Medicine and Biology</i> , 2016, 61, 2319-2332.	3.0	17
60	[ $^{18}\text{F}$ ]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. <i>Bioconjugate Chemistry</i> , 2016, 27, 1655-1662.	3.6	15
61	(2 <i>S</i> )-2-(3-(1-Carboxy-5-( $^{211}\text{At}$ -Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted $\alpha$ -Particle Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1569-1575.	5.0	101
62	Pharmacokinetic modeling of [ $^{18}\text{F}$ ]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. <i>EJNMMI Research</i> , 2016, 6, 28.	2.5	7
63	Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. <i>Cancer Research</i> , 2016, 76, 472-479.	0.9	140
64	Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. <i>Oncotarget</i> , 2016, 7, 33306-33315.	1.8	25
65	Development of a defect model for renal pediatric SPECT imaging research. , 2015, , .		5
66	Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma. <i>Practical Radiation Oncology</i> , 2015, 5, 219-227.	2.1	7
67	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. <i>EJNMMI Physics</i> , 2015, 2, 5.	2.7	10
68	Initial Evaluation of [ $^{18}\text{F}$ ]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 565-574.	2.6	378
69	Preclinical Evaluation of $^{86}\text{Y}$ -Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. <i>Journal of Nuclear Medicine</i> , 2015, 56, 628-634.	5.0	35
70	Strengths and Weaknesses of a Planar Whole-Body Method of $^{153}\text{Sm}$ Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 369-379.	1.0	9
71	The Role of Preclinical Models in Radiopharmaceutical Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e121-e125.	3.8	6
72	Development and evaluation of convergent and accelerated penalized SPECT image reconstruction methods for improved dose-volume histogram estimation in radiopharmaceutical therapy. <i>Medical Physics</i> , 2014, 41, 112507.	3.0	2

#	ARTICLE	IF	CITATIONS
73	Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy. Radiation Research, 2014, 181, 90-98.	1.5	40
74	Radiopharmaceutical therapy in the era of precision medicine. European Journal of Cancer, 2014, 50, 2360-2363.	2.8	16
75	MIRD Pamphlet No. 24: Guidelines for Quantitative <sup>131</sup> I SPECT in Dosimetry Applications. Journal of Nuclear Medicine, 2013, 54, 2182-2188.	5.0	125
76	Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma. Journal of Nuclear Medicine, 2013, 54, 1535-1542.	5.0	20
77	Evaluation of image quality using Channelized Hotelling observer for pediatric diagnostic imaging of <sup>99m</sup> Tc-dimercaptosuccinic acid. , 2013, , .		0
78	Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy. Radiation Research, 2013, , 131230084310008.	1.5	0
79	Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup> F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2012, 53, 1883-1891.	5.0	264
80	Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?. Antibodies, 2012, 1, 124-148.	2.5	16
81	MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy. Journal of Nuclear Medicine, 2012, 53, 1310-1325.	5.0	293
82	A nephron-based model of the kidneys for macro-to-micro $\hat{\pm}$ -particle dosimetry. Physics in Medicine and Biology, 2012, 57, 4403-4424.	3.0	48
83	Internal photon and electron dosimetry of the newborn patientâ€”a hybrid computational phantom study. Physics in Medicine and Biology, 2012, 57, 1433-1457.	3.0	20
84	A bone marrow toxicity model for <sup>223</sup> Ra alpha-emitter radiopharmaceutical therapy. Physics in Medicine and Biology, 2012, 57, 3207-3222.	3.0	105
85	Three-dimensional radiobiological dosimetry (3D-RD) with <sup>124</sup> I PET for <sup>131</sup> I therapy of thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 41-47.	6.4	52
86	A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1256-1262.	0.8	49
87	2-(3-{1-Carboxy-5-[(6-[ <sup>18</sup> F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [ <sup>18</sup> F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. Clinical Cancer Research, 2011, 17, 7645-7653.	7.0	331
88	An Approach for Balancing Diagnostic Image Quality with Cancer Risk: Application to Pediatric Diagnostic Imaging of <sup>99m</sup> Tc-Dimercaptosuccinic Acid. Journal of Nuclear Medicine, 2011, 52, 1923-1929.	5.0	33
89	Sequential Cytarabine and $\hat{\pm}$ -Particle Immunotherapy with Bismuth-213â€™Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5303-5311.	7.0	234
90	<sup>124</sup> I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison. Journal of Nuclear Medicine, 2009, 50, 1844-1847.	5.0	80

#	ARTICLE	IF	CITATIONS
91	MIRD Commentary: Proposed Name for a Dosimetry Unit Applicable to Deterministic Biological Effectsâ€”The Barendsen (Bd). <i>Journal of Nuclear Medicine</i> , 2009, 50, 485-487.	5.0	31
92	Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. <i>Medical Physics</i> , 2009, 36, 612-619.	3.0	46
93	MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetryâ€”Standardization of Nomenclature. <i>Journal of Nuclear Medicine</i> , 2009, 50, 477-484.	5.0	633
94	Calculation of the biological effective dose for piecewise defined doseâ€”rate fits. <i>Medical Physics</i> , 2009, 36, 904-907.	3.0	30
95	Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planningâ€”Monte Carlo Simulation Studies. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 521-530.	8.9	48
96	Alpha-particles for targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1402-1406.	13.7	107
97	Three-Dimensional Imaging-Based Radiobiological Dosimetry. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 321-334.	4.6	82
98	Cancer Stem Cell Targeting Using the Alpha-Particle Emitter, <sup>213</sup> Bi: Mathematical Modeling and Feasibility Analysis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 74-81.	1.0	22
99	<i>Update:</i> Molecular Radiotherapy: Survey and Current Status. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 531-540.	1.0	7
100	Toward Patient-Friendly Cell-Level Dosimetry. <i>Journal of Nuclear Medicine</i> , 2007, 48, 496-497.	5.0	11
101	MIRD Continuing Education: Bystander and Low Dose-Rate Effects: Are These Relevant to Radionuclide Therapy?. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1683-1691.	5.0	53
102	Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1977-84.	5.0	34
103	Dosimetry of internal emitters. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 18S-27S.	5.0	40
104	Introduction to Kidney Doseâ€”Response for Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 357-358.	1.0	3
105	Targeted $\alpha$ particle immunotherapy for myeloid leukemia. <i>Blood</i> , 2002, 100, 1233-1239.	1.4	430
106	Targeted alpha particle immunotherapy for myeloid leukemia. <i>Blood</i> , 2002, 100, 1233-9.	1.4	143
107	Long-lived Alpha Emitters in Radioimmunotherapy: The Mischievous Progeny. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 219-221.	1.0	8